News Focus
News Focus
Followers 41
Posts 9106
Boards Moderated 4
Alias Born 09/06/2014

Re: seven-up post# 91909

Thursday, 01/05/2017 10:55:54 AM

Thursday, January 05, 2017 10:55:54 AM

Post# of 351585
Investing based on Testimonials and Surveys is speculation, nothing more.

The SCIENCE here says the ActiPatch reduces VAS scores by a couple of digits. None of the scientific trials show the ActiPatch eliminating pain -- the ActiPatch merely reduces pain, and only by a little.

That's not going to get people off opioids, it's not going to stop doctors from prescribing opioids, and it's not going to prevent people from using opioids, except perhaps on a VERY small scale.

This whole idea that the ActiPatch is going to make even a tiny dent in opioid use or addiction is laughable, at best. Doctors don't prescribe opioids for every little injury. When I got my rotator cuff injury last year, my doctor didn't prescribe opioids. When I got hit by a car in a parking lot on Monday night (I was a pedestrian, the car ran a stop sign going about 15 mph), and I went to the ER, the doctor didn't prescribe opioids. My friend, on the other hand, broke his humerus -- a radial compound fracture - and he was prescribed opioids.

Opioids have little to do with the failure or success of the ActiPatch as a retail product. If the ActiPatch had shown some success in the UK I'd feel differently but it was a failure in the UK. It's going to be a retail failure in the USA too unless the price comes down. At $30 or $35 or whatever it's going to cost, most OTC pain customers will pass on the ActiPatch -- exactly what happened in the UK.